drugset
drugset / Trial / NCT02144675

Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

NCT02144675 ↗

Phase 2 Completed 27 enrolled Rutgers, The State University of New Jersey National Cancer Institute (NCI) · collabRutgers Cancer Institute of New Jersey · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized phase II trial studies how well choline magnesium trisalicylate with idarubicin and cytarabine works in treating patients with acute myeloid leukemia. Drugs used in chemotherapy, such as choline magnesium trisalicylate, idarubicin, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet know whether choline magnesium trisalicylate and combination chemotherapy is more effective than combination chemotherapy alone in treating patients with acute myeloid leukemia.

Timeline

Start
2009-01
Primary completion
2016-04-26
Completion
2016-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject choline magnesium trisalicylate Unknown — Oral
Background Cytarabine Small molecule — Intravenous
Background Idarubicin Small molecule — Intravenous

Indications

acute erythroid leukemia acute megakaryoblastic leukemia in adult acute myeloblastic leukemia with maturation acute myeloblastic leukemia without maturation acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with minimal differentiation acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, del(5q31-q32) acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) acute myelomonocytic leukemia M4 adult acute monocytic leukemia